Heparin sodium is an anticoagulant commonly used to prevent and treat thrombosis and cardiovascular diseases. It is a polysaccharide substance that can prevent blood clotting by inhibiting the activity of thrombin. Heparin sodium is usually administered by injection and can be used for preventive anticoagulation therapy before and after surgery, as well as for the treatment of diseases such as deep vein thrombosis and pulmonary embolism.

According to different molecular weights and preparation methods, heparin sodium can be divided into two categories: standard heparin sodium and low-molecular-weight heparin sodium. Standard heparin sodium is the most commonly used heparin sodium, which has a low molecular weight and high anticoagulant activity. It is usually extracted from the intestinal mucosa of pigs or the lungs of cows; Low-molecular-weight heparin sodium is obtained by chemical or biological degradation of standard heparin sodium, which has stronger anticoagulant activity and fewer side effects compared to standard heparin sodium.

According to our research data, the global heparin sodium market revenue is expected to reach $2812 million in 2023, among which the low-molecular-weight heparin sodium segment market will dominate, with an estimated market revenue of $1901 million in 2023 and an estimated market share of 67.61%. In the future, as people\'s attention to cardiovascular diseases and thrombosis continues to increase, coupled with the continuous progress of technology and the development of new drugs, the application prospects of heparin sodium will become increasingly broad, and its market will continue to expand. It is expected that the global heparin sodium market revenue will reach $3706 million by 2026.

Source: www.globalmarketmonitor.com

The concentration of the global heparin sodium market is moderate, with the main companies coming from China and Spain. Data shows that the total revenue of the top 3 companies in the heparin sodium industry was $916 million in 2020, accounting for 31.79% of the market. The total revenue of the top 6 companies was $1532 million, with a total market share of 53.18%. The top three companies in the rankings were Shenzhen Hepalink Pharmaceutical Co., Ltd., Bioiberica S.A., and Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd. In 2020, the three companies accounted for 12.77%, 10.86%, and 8.16% of the global market revenue for heparin sodium, respectively.

Global Heparin Sodium Market Revenue and Share by Enterprise in 2020

Enterprises	Market Revenue (M USD)	Market Share
Shenzhen Hepalink Pharmaceutical Co., Ltd.	3.68	12.77%
Bioiberica S.A.	3.13	10.86%
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd.	2.35	8.16%
Top3	9.16	31.79%
Top6	15.32	53.18%

Source: www.globalmarketmonitor.com